目的： 建立三阴性乳腺癌紫杉醇耐药细胞株并考察FA/BRCA通路相关基因FANCF在该细胞株紫衫醇耐药中的作 用。 方法： 以药物浓度递增法诱导三阴性乳腺癌细胞MDA-MB-231成为紫杉醇耐药细胞株，采用CCK8法检测细胞的耐药指 数，流式细胞术检测细胞的生长周期，qRT-PCR检测FA/BRCA通路相关基因FANCF的表达；Western blotting 法验证相关蛋白的 表达。对MDA-MB-231敏感细胞和紫杉醇耐药细胞中FANCF的表达进行敲减，并在mRNA和蛋白水平进行敲减效果验证，以 CCK8法检测紫杉醇对该两种细胞的IC 50 。 结果： MDA-MB-231细胞紫杉醇诱导3个月后的耐药指数为9.9，该细胞的G0/G1期 细胞增多且S期细胞减少，细胞中FANCF mRNA和蛋白表达水平显著升高。FANCF敲低后无论MDA-MB-231还是MDA-MB- 231/PTX细胞的凋亡增加，对紫杉醇敏感性显著升高(P<0.05或P<0.01)。 结论： FANCF基因在乳腺癌紫杉醇耐药中具有重要作 用，可能是乳腺癌治疗的一个潜在靶点。

Objective: To establish paclitaxel(PTX)-resistant human triple negative breast cancer cell line and to examine the expres- sion profile of FA-related genes and FANCF, the correlation between the expression of FA-related genes, FANCF and PTX-resistance in breast cancer were further analyzed. Methods: PTX-resistant MDA-MB-231 cell line was established by means of long-term PTX-ex- posed culture. The sensitivity of the cells to paclitaxel was determined by the CCK8 assay. The cell cycle distribution was examined by flow cytometry after exposure to the paclitaxel. The expression of FA-related gene mRNA and FANCF protein were examined by using real time quantitative PCR and Western blotting. The expression of FANCF in the cells was reduced by RNAi interference technology and the effect of the RNAi was verified. Results: MDA-MB-231/PTX cell showed a 9.9-fold resistance to paclitaxel, indicating that the cell had acquired resistance to PTX. PTX treatment significantly induced G0/G1 arrest and the number of cells in phase S markedly de- creased after exposure to PTX. The mRNA and protein expression of FANCF was significantly higher in PTX-resistant cell than that in PTX-sensitve parental cell，Knockdown of FANCF induced apoptosis in MDA-MB-231/PTX cell as well as in parental cell. FANCF knockdown increased the sensitivity of paclitaxel to both MDA-MB-231 and MDA-MB-231/PTX cells (P<0.05 or P<0.01). Conclu- sion: FANCF played an important role in PTX resistance of the breast cancer cells and FANCF might be a target for therapy aimed at re- versing chemoresistance.

国家自然科学基金项目（No.81660472）；云南省卫生系统领军人才培养计划（No.L-201212）；云南省细胞治疗技术转化医学 重点实验室基金（No.2015DG034）。